News & Updates
Filter by Specialty:
Weight loss boosts response to intrauterine progestin
Among women with obesity and atypical hyperplasia or low-risk endometrial cancer, weight loss during conservative management with intrauterine progestin improves treatment outcomes, according to a study.
Weight loss boosts response to intrauterine progestin
03 Nov 2021SCLC: Hippocampal avoidance in prophylactic cranial irradiation a potential SoC
In patients with small-cell lung cancer (SCLC), hippocampal avoidance-prophylactic cranial irradiation (HA-PCI) better preserves cognitive function and has no adverse impact on the incidence of brain metastases, overall survival (OS) and quality of life (QoL) compared with standard PCI, a phase III randomized controlled trial has shown.
SCLC: Hippocampal avoidance in prophylactic cranial irradiation a potential SoC
03 Nov 2021Add-on brivaracetam for epilepsy makes good in real-world practice
Long-term postmarketing data for adjunctive brivaracetam show that its use helps improve seizure control in patients with various epilepsy syndromes, even in those with prior exposure to levetiracetam. However, psychobehavioural adverse events (AEs) occur in one out of ten patients.
Add-on brivaracetam for epilepsy makes good in real-world practice
02 Nov 2021Transplantation bias, misconceptions endure for alcohol-, obesity-related liver disease
Bias and misconceptions about liver transplantation persist for patients with alcohol- (ALD) and obesity-related liver disease (OLD), a study has found.
Transplantation bias, misconceptions endure for alcohol-, obesity-related liver disease
02 Nov 2021Omission of parametrial boost does not compromise local control, survival in modern era
Leaving out the use of external beam parametrial boost (EBPB) for locally advanced cervical cancer does not seem to negatively affect local control or survival in the era of image-guided brachytherapy, results of a study have shown. This then supports a reduced need for standardized use of parametrial boost.
Omission of parametrial boost does not compromise local control, survival in modern era
02 Nov 2021Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.